Continuity at the head of the Management Board / Gerresheimer CEO Dr. Axel Herberg hands over top job to Uwe Röhrhoff in June

Dusseldorf (ots) - Chief Executive Officer Dr. Axel Herberg (51)
is not seeking reappointment and will leave the Management Board when
his contract expires in June. The Supervisory Board has received this
decision with regret and in its meeting today appointed as Herberg's
successor from June the Management Board member of many years'
standing, Uwe Röhrhoff (47).

Herberg looks back over almost twenty years in top management with
Gerresheimer. Particularly in his ten years as CEO, he has shaped the
Düsseldorf company's development into an internationally leading
supplier to the pharma and healthcare industry and was also
instrumental in the successful flotation of Gerresheimer AG, which is
now listed on the M-Dax. Herberg has worked side by side with his
successor in a relationship of mutual trust for many years. Röhrhoff
stands for continuity and experience at the top of the business and
has already been with Gerresheimer for twenty years. He was appointed
to the Management Board in 2003 and, for example, bore key
responsibility for development of Gerresheimer's important US and
Chinese business.

"The Supervisory Board is extremely sorry that Dr. Herberg is
leaving the Management Board. He has developed Gerresheimer into a
very successful global supplier for the pharma industry. The
Supervisory Board therefore unanimously recommends that Dr. Herberg
is elected to this body. We are pleased to have Uwe Röhrhoff as the
new CEO at the head of the business from the summer. Mr Röhrhoff is
ideal for this position and, thanks to his extraordinary specialist
knowledge and industry expertise, enjoys a high level of trust among
employees and customers," said Supervisory Board Chairman Gerhard
Schulze.

Axel Herberg commented: "The Gerresheimer Group is excellently
positioned. The strategy to focus on pharma and healthcare with
leading worldwide market positions has proven itself particularly
during the crisis. With Uwe Röhrhoff, who I've worked with closely
for almost twenty years, the company is in ideal hands."

In today's meeting of the Supervisory Board, Hans-Jürgen Wiecha
(47), who has been with the company for ten years, including five
years on the Management Board with responsibility for finance, was
also appointed as Chief Financial Officer for a further five years.

About Gerresheimer

Gerresheimer employs around 9,400 people in 40 locations in
Europe, Americas and Asia. In the financial year 2009, worldwide
sales totaled EUR 1 billion. The product portfolio ranges from
pharmaceutical vials made of glass and plastic through to complex
drug-delivery systems for the pharma & healthcare industry. These
include sterile syringes, inhalers and other system-based approaches
for safe dosage and application of medications. The Group enjoys a
leading position in markets which are characterized by high technical
and regulatory barriers.

Originaltext: Gerresheimer AG
digital press kits: http://www.presseportal.de/pm/9072
press kits via RSS: http://www.presseportal.de/rss/pm_9072.rss2
ISIN: DE000A0LD6E6

Contact Press
Burkhard Lingenberg
Director Corporate Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
e-mail b.lingenberg@gerresheimer.com

Contact Investor Relations
Anke Linnartz
Director Corporate Investor Relations
Phone +49 211 6181-314
e-mail a.linnartz@gerresheimer.com
Fax +49 211 6181-121